Cost-effectiveness and carbon footprint of cystoscopic surveillance schedules in non-muscle-invasive bladder cancer

Abstract Repeated cystoscopy for non-muscle-invasive bladder cancer incurs costs and greenhouse-gas emissions, but fewer examinations may delay recurrence detection. We compared nine surveillance schedules in a 15-year monthly cohort model stratified by European Association of Urology risk group. We used 2021 United States costs and an international emissions inventory. In low-risk patients, ending scheduled surveillance after the three-month examination, while retaining investigation of symptoms, reduced modelled costs by 24.0% and inventoried emissions by 13.0% compared with guideline follow-up. Time spent with undetected recurrence increased. In 5,000 paired simulations, the mean difference in quality-adjusted life-years for this low-risk comparison was 0.009 per patient (95% uncertainty interval, -0.260 to 0.291). Clinical results depended on progression before recurrence detection and diagnosis prompted by symptoms; less favourable assumptions increased progression and bladder-cancer deaths. Recurrence treatment accounted for most inventoried emissions, limiting the carbon savings from fewer cystoscopies. Selected reductions in low-risk surveillance warrant prospective evaluation, but the model does not establish the safety of stopping scheduled surveillance after one examination.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-15
DOI
https://doi.org/10.1038/s41598-026-79726-1
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Cost-effectiveness and carbon footprint of cystoscopic surveillance schedules in non-muscle-invasive bladder cancer

Chunxiao Yu
2 links
Scientific Reports
Bladder and Urothelial Cancer Treatments
article

Cost-effectiveness and carbon footprint of cystoscopic surveillance schedules in non-muscle-invasive bladder cancer

Chunxiao Yu
article en

Abstract

Abstract Repeated cystoscopy for non-muscle-invasive bladder cancer incurs costs and greenhouse-gas emissions, but fewer examinations may delay recurrence detection. We compared nine surveillance schedules in a 15-year monthly cohort model stratified by European Association of Urology risk group. We used 2021 United States costs and an international emissions inventory. In low-risk patients, ending scheduled surveillance after the three-month examination, while retaining investigation of symptoms, reduced modelled costs by 24.0% and inventoried emissions by 13.0% compared with guideline follow-up. Time spent with undetected recurrence increased. In 5,000 paired simulations, the mean difference in quality-adjusted life-years for this low-risk comparison was 0.009 per patient (95% uncertainty interval, -0.260 to 0.291). Clinical results depended on progression before recurrence detection and diagnosis prompted by symptoms; less favourable assumptions increased progression and bladder-cancer deaths. Recurrence treatment accounted for most inventoried emissions, limiting the carbon savings from fewer cystoscopies. Selected reductions in low-risk surveillance warrant prospective evaluation, but the model does not establish the safety of stopping scheduled surveillance after one examination.

Scientific Reports
Zaozhuang Municipal Hospital (CN)
Good health and well-being, Responsible consumption and production, Climate action
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon